A lovely #EvidentlyCochrane summary on our LAMA for Asthma: https://t.co/PlzPZZa8od #WorldAsthmaDay More evidence: https://t.co/FWCNP05jBJ
RT @CochraneAirways: Stopping LABA in adults on combination of LABA and ICS may increase likelihood of asthma attack https://t.co/J6F9bbcFN…
RT @CochraneAirways: Stopping LABA in adults on combination of LABA and ICS may increase likelihood of asthma attack https://t.co/J6F9bbcFN…
RT @CochraneAirways: Stopping LABA in adults on combination of LABA and ICS may increase likelihood of asthma attack https://t.co/J6F9bbcFN…
Stopping LABA in adults on combination of LABA and ICS may increase likelihood of asthma attack https://t.co/J6F9bbcFNZ #WorldAsthmaDay
Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled… https://t.co/jgzhB3bMMF
New #Cochrane review: Stopping LABA for children with asthma well controlled on LABA and ICS - sadly no trials http://t.co/Xc53zFPHJt
FDA warn against LABA long term in #asthma; instead use for symptom control. #Cochrane review: http://t.co/U0XIEAyVn7 via @CochraneLibrary
New #Cochrane review: Stopping LABA for children with asthma well controlled on LABA and ICS - sadly no trials http://t.co/Xc53zFPHJt
MT @CochraneAirways: FDA warn against LABA long term in #asthma; instead use for symptom control. We review evidence: http://t.co/xm7w7XdrE3
No eligible RCTs in children, but we have a review on adults which has data and should be published in 2 weeks http://t.co/UnnmfckXHe
New #Cochrane review: Stopping LABA for children with asthma well controlled on LABA and ICS - sadly no trials http://t.co/Xc53zFPHJt
New #Cochrane review: Stopping LABA for children with asthma well controlled on LABA and ICS - sadly no trials http://t.co/Xc53zFPHJt
No eligible RCTs in children, but we have a review on adults which has data and should be published in 2 weeks http://t.co/UnnmfckXHe
MT @CochraneAirways: FDA warn against LABA long term in #asthma; instead use for symptom control. We review evidence: http://t.co/xm7w7XdrE3
MT @CochraneAirways: FDA warn against LABA long term in #asthma; instead use for symptom control. We review evidence: http://t.co/xm7w7XdrE3
MT @CochraneAirways: FDA warn against LABA long term in #asthma; instead use for symptom control. We review evidence: http://t.co/xm7w7XdrE3
MT @CochraneAirways: FDA warn against LABA long term in #asthma; instead use for symptom control. We review evidence: http://t.co/xm7w7XdrE3
#Rev_Sist #Cochra Detención #ABAP en niños con #asma bien controlado en terapia combinada http://t.co/jEWnsvWnuJ @aepediatria @evidpediatria
FDA warn against using LABA long term in #asthma; instead use for symptom control. We wanted to review evidence http://t.co/rHcx9cmYqF
No eligible RCTs in children, but we have a review on adults which has data and should be published in 2 weeks http://t.co/UnnmfckXHe
FDA warn against using LABA long term in #asthma; instead use for symptom control. We wanted to review evidence http://t.co/rHcx9cmYqF
New #Cochrane review: Stopping LABA for children with asthma well controlled on LABA and ICS - sadly no trials http://t.co/Xc53zFPHJt
New #Cochrane review: Stopping LABA for children with asthma well controlled on LABA and ICS - sadly no trials http://t.co/Xc53zFPHJt
#Rev_Sist #Cochra Detención #ABAP en niños con #asma bien controlado en terapia combinada http://t.co/jEWnsvWnuJ @aepediatria @evidpediatria
Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled… http://t.co/9vPsPyv60u
Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled… http://t.co/SvInmvWA2d